Charles Swingland is Deputy Chairman of Drayson Technologies. In 1996, after several years as a partner in a law firm in the City of London, Charles joined PowderJect Pharmaceuticals Plc as Senior Vice President of Corporate Services and General Counsel.
At PowderJect, Charles was responsible for all legal, intellectual property and compliance matters and managed the legal aspects of several major acquisitions and fundraisings, including its eventual sale, in 2003, to Chiron for $1 billion.
In 2004, he was part of the senior management team of Zeneus Pharma, which was backed by the private equity investor, Apax Partners, to acquire the European specialty pharmaceutical business of Elan Pharmaceuticals. During his time at Zeneus he oversaw all the company’s commercial transactions, including the acquisition of the original assets, the in-licensing of several new pharmaceutical products and the eventual sale to Cephalon Inc. in 2005.
In 2006, Charles co-founded Circassia Pharmaceuticals which went public in March 2014 in the largest ever initial public offering of shares by a European biotechnology company. Charles remains non-executive Deputy Chairman of Circassian, but stood down as an executive at the time of its IPO.
He joined Drayson Technologies in May 2014.
Charles is a former Trustee and current member of the Board of Advisors of the Earthwatch Institute, an international charity concerned with conservation of the environment and education.